Teva and Mylan Settle Copaxone Patent Litigation in France, the UK and the Netherlands

28-11-2013 Business Wire HealthComments (0)

CopaxoneGenericsMylan LaboratoriesTeva Pharmaceutical Industries

Teva Pharmaceutical Industries (NYSE:TEVA) and Mylan Inc. (NASDAQ:MYL) today announce that certain of their affiliates have agreed to settle and dismiss pending patent litigation involving Copaxone (glatiramer acetate) in the United Kingdom, the Netherlands and France relating to non-infringement and the validity of European Patent 0,762,888, which expires in May 2015. The terms of the settlement are confidential. About Teva Teva Pharmaceutical Industries Ltd. (NYSE

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top